BioViva CEO Liz Parrish on Becoming Gene Therapy Test Subject episode artwork

EPISODE · Jan 23, 2016 · 57 MIN

BioViva CEO Liz Parrish on Becoming Gene Therapy Test Subject

from Singularity.FM · host Nikola Danaylov

Last time I interviewed BioViva CEO Liz Parrish I had no idea that she would make global headlines shortly thereafter by becoming a gene therapy test subject herself. And so I wanted to bring her back to discuss the kind of experiment she volunteered for, as well as the broad science behind it. So, 4 months after receiving gene therapies aimed at reversing muscle-wasting disease and aging, I finally managed to get Liz on my Singularity 1on1 podcast. During our 60 min conversation with Liz Parrish we cover a variety of interesting topics such as: why she decided to target these particular diseases – sarcopenia and aging; why Parrish thinks that testing them both at once is a good thing; the best and worst case outcome scenarios; the potential bio-markers that can confirm or deny the efficacy of these therapies; the test protocol and timeline for any definitive results; the costs associated with such treatments and why insurance companies and governments will have an incentive to pay; Zoltan Istvan’s presidential candidacy and his campaign against death; her take on CRISPR and gene editing… You can watch the full video here: https://www.singularityweblog.com/bioviva-ceo-liz-parrish-on-becoming-gene-therapy-test-subject/

Last time I interviewed BioViva CEO Liz Parrish I had no idea that she would make global headlines shortly thereafter by becoming a gene therapy test subject herself. And so I wanted to bring her back to discuss the kind of experiment she volunteered for, as well as the broad science behind it. So, 4 months after receiving gene therapies aimed at reversing muscle-wasting disease and aging, I finally managed to get Liz on my Singularity 1on1 podcast. During our 60 min conversation with Liz Parrish we cover a variety of interesting topics such as: why she decided to target these particular diseases – sarcopenia and aging; why Parrish thinks that testing them both at once is a good thing; the best and worst case outcome scenarios; the potential bio-markers that can confirm or deny the efficacy of these therapies; the test protocol and timeline for any definitive results; the costs associated with such treatments and why insurance companies and governments will have an incentive to pay; Zoltan Istvan’s presidential candidacy and his campaign against death; her take on CRISPR and gene editing… You can watch the full video here: https://www.singularityweblog.com/bioviva-ceo-liz-parrish-on-becoming-gene-therapy-test-subject/

NOW PLAYING

BioViva CEO Liz Parrish on Becoming Gene Therapy Test Subject

0:00 57:50

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Singularity.FM?

This episode is 57 minutes long.

When was this Singularity.FM episode published?

This episode was published on January 23, 2016.

What is this episode about?

Last time I interviewed BioViva CEO Liz Parrish I had no idea that she would make global headlines shortly thereafter by becoming a gene therapy test subject herself. And so I wanted to bring her back to discuss the kind of experiment she...

Can I download this Singularity.FM episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!